Bristol Myers Squibb Admilparant Phase 3 Trial Meets Primary Endpoint
Key Facts
Bristol Myers Squibb announced that the Phase 3 ALOFT-IPF trial evaluating Admilparant met its primary endpoint. The company stated in a release via Business Wire that the positive top-line results were observed in adults suffering from idiopathic pulmonary fibrosis (IPF).
The successful clinical trial marks a critical milestone for the drug's path toward regulatory approval. These developments highlight the company's progress in developing treatments for serious lung diseases as it continues to advance its specialized pharmaceutical pipeline.
Latest Updates · 1
- Notable·
Update: Bristol Myers Squibb reported on October 12, 2026, positive top-line results from an interim analysis of the Phase 3 ACTION-1 trial for RYZ101. The trial demonstrated efficacy in patients with gastroenteropancreatic neuroendocrine tumors, further expanding the company's oncology pipeline.